CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

CDMO Subsection

Insights into the latest developments in CDMO services and manufacturing.

Continue reading

Injectables Subsection

Expert perspectives on the evolving needs of injectable therapies and packaging.

Continue reading

Nasal & Pulmonary Subsection

Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability

Continue reading

Advertisement

CPHI Milan
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Advertisement

Solstice

HBP Biomarkers and Assay Development within Laboratory Practice

“Sepsis is the most preventable cause of death”, and every hour it is not diagnosed will increase the probability it will kill the patient by 7%, so recognising the early signs and symptoms is therefore crucial. Because HBP (heparin binding protein), also known as cationic antimicrobial protein of 37kDa (CAP37) and azurocidin, directly contributes to the maintenance and progression of inflammation, Christine Leiper from Onorach explains that it is a potential diagnostic marker for the assessment of patients at risk of sepsis and should be studied further in large-scale clinical studies.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026